IN THE NEWS / PRESS RELEASE

JUNE 7, 2023

London, UK, Vancouver, Toronto Canada, June 7, 2023 — 4C LABS Ltd. (the “Company” or “4C LABS Ltd”) is pleased to announce that it has entered into a strategic distribution agreement with MAMEDICA (“Mamedica”), a leading medical cannabis clinic and pharmacy based in London.  Mamedica and 4C LABS expect to commercialise medical cannabis products under The Green Organic Dutchman brand & other to-be-announced brands in the UK, commencing September this year.

Pursuant to the agreement, 4C LABS will supply Mamedica with curated, EU GMP Medical Cannabis products which will be available through Mamedica’s Dispensary.

Mamedica is one of the fastest-growing clinics in the UK’s emerging medical cannabis market.  Testament to this, the service has witnessed a 400% increase in patient numbers through 2023.  Looking to the future, Mamedica expects that this progression will continue over the coming
years and aims to become one of the largest clinic and pharmacy operators in the UK.

Mamedica has identified several factors that contribute to customer dissatisfaction, including product quality, cost, service, and supply chain challenges. Recognising the pivotal role of customer experience in driving market growth, Mamedica is taking proactive steps to address these concerns. Therefore, in a progressive move to provide customers with the world’s best EU GMP products, Mamedica’s partnership with 4C LABS offers competitive price points and a guaranteed excellent customer service experience.

4C LABS product lines are composed of products from The Green Organic Dutchman, a premier, certified organic grower of medical cannabis in living soil, this comes alongside other to-be-announced brands. The Green Organic Dutchman recently received EU GMP certification for its greenhouse facilities located in Ancaster, Ontario, Canada. This certification permits the company to export specific medical cannabis products to numerous global markets, including the UK.

The growing company believes that there is strong demand for quality amongst consumers of cannabis products in the UK & Channel Islands. The team at 4C LABS anticipate the market to expand over the next five years, mirroring previously legalised medical markets elsewhere. This
agreement is expected to help establish a leading position for 4C LABS in the UK & Channel Islands medical cannabis markets.

The new collaboration between Mamedica and 4C LABS brings exciting benefits to patients in the UK by providing access to high-quality products that have already proven successful in Canada, renowned as the world’s most advanced cannabis market. The Green Organic Dutchman products mark the first of many new products being introduced to the UK & Channel Islands.  These products will be launched in September 2023 and made with unbeatable quality and compelling price points.

Greg Dobbin, 4C LABS’ CEO, stated: “We are extremely pleased to be able to offer The Green Organic Dutchman products to Mamedica patients. Mamedica is a best-in-class company whose focus on patient satisfaction will ensure strong future growth.”

Jon Robson, Mamedica’s CEO and founder stated: “We are pleased to announce our partnership with 4C LABS to introduce their esteemed portfolio of Canadian medical cannabis products to the UK market. We eagerly anticipate the introduction of 4C LABS’ highly regarded EU GMP products and we are excited to collaborate with industry experts such as Greg and James.”

About MAMEDICA.
MAMEDICA is a private clinic with linked pharmacy which specialises in cannabis based prescriptions, for patients who have not found satisfactory results for their pain, psychiatry, neurology, palliative care or cancer related conditions with their existing medications.  Founded by Jon Robson, and launched in 2022, Mamedica aims to deliver a quality of service which is currently lacking in the medical cannabis sector. Mamedica puts patient safety, security and satisfaction at the forefront of every activity, using only the most high-calibre consultants and support staff as part of their team. For more information, please visit www.mamedica.com

About 4C LABS Ltd.
4C LABS Ltd. is an EIS registered, privately held UK Medical Cannabis company focusing on providing patients with world-class Medical Cannabis products at an affordable price. 4C LABS has import and distribution licenses in the UK and a wide network of pharmacies in the UK & Channel Islands. 4C LABS carries a full product line of Medical Cannabis from a selected network of trusted international cultivation partners. Products will be available in the UK & Channel Islands in Q4 2023. For more information, please visit www.4clabs.co

MAMEDICA & 4C LABS Ltd.

For further information (MAMEDICA): Eleanor Shaw, PR: eleanor@mamedica.com | +44 330 580 1170

For further information (4C LABS Ltd.): Greg Dobbin, CEO: greg@4clabs.ca | +1-604-603-5333

Cautionary Statements
This news release includes statements containing certain “forward–looking information” within the meaning of applicable securities law (“forward–looking statements”). Forward looking statements in this release include, but are not limited to, statements about future production quantity and timing, statements about the offering of any particular products by the Company and statements regarding the future performance of the Company, statements about funding availability, statements about growth and delivery of products, and statements about the level of demand for 4C LABS’s products, statements relating to the creation and timing of any revenue in the UK, and statements about the future size of any international markets. Forward–looking statements are frequently characterized by words such as “plan”, “continue”, “expect”, “project”, “intend”, “should”, “believe”, “anticipate”, “estimate”, “may”, “will”, “potential”, “proposed” and other similar words, or statements that certain events or conditions “may” or “will” occur. These statements are only predictions. Various assumptions were used in drawing the conclusions or making the projections contained in the forward–looking statements throughout this news release, such as assumptions that the Company’s financial trajectory will continue, the Company not having any issues with regulators, cultivation patterns at the Company’s facilities continuing and there not being significant disruptions in cultivation such as disease or shortages in resources, the Company being insulated from supply chain issues and inflation affecting the global economy, the Company being able to access the capital markets and existing lenders for necessary funding, when necessary, demand for the Company’s products continuing as expected and based on past trends. Forward–looking statements are based on the opinions and estimates of management at the date the statements are made and are subject to a variety of risks and uncertainties (including market conditions) and other factors that could cause actual events or results to differ materially from those projected in the forward–looking statements, including those risk factors described in Management’s Discussion and Analysis and the Company’s most recent Annual Information Form filed with Canadian securities regulators and available on the Company’s issuer profile on SEDAR at www.sedar.com. Although the Company believes that the assumptions and factors used in preparing the forward-looking information or forward-looking statements in this news release are reasonable, undue reliance should not be placed on such information and no assurance can be given that such events will occur in the disclosed time frames or at all. The forward-looking information and forward-looking statements included in this news release are made as of the date of this news release. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward–looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.